{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:44Z","timestamp":1790740724306,"version":"4.1.0"},"reference-count":79,"publisher":"American Chemical Society (ACS)","issue":"6","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Centers for Disease Control and the World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant Neisseria gonorrheae, for which novel oral agents are urgently needed. Zoliflodacin, the first in a new class of antibacterial agents called the spiropyrimidinetriones, is being developed for the treatment of gonorrhea. It has a unique mode of inhibition against bacterial type II topoisomerases with binding sites in bacterial gyrase that are distinct from those of the fluoroquinolones. Zoliflodacin is bactericidal, with a low frequency of resistance and potent antibacterial activity against N. gonorrheae, including multi-drug-resistant strains (MICs ranging from \u22640.002 to 0.25 \u03bcg\/mL). Although being developed for the treatment of gonorrhea, zoliflodacin also has activity against Gram-positive, fastidious Gram-negative, and atypical pathogens. A hollow-fiber infection model using S. aureus showed that that pharmacokinetic\/pharmacodynamic index of fAUC\/MIC best correlated with efficacy in in vivo neutropenic thigh models in mice. This data and unbound exposure magnitudes derived from the thigh models were subsequently utilized in a surrogate pathogen approach to establish dose ranges for clinical development with N. gonorrheae. In preclinical studies, a wide safety margin supported progression to phase 1 studies in healthy volunteers, which showed linear pharmacokinetics, good oral bioavailability, and no significant safety findings. In a phase 2 study, zoliflodacin was effective in treating gonococcal urogenital and rectal infections. In partnership with the Global Antibiotic Research Development Program (GARDP), zoliflodacin is currently being studied in a global phase 3 clinical trial. Zoliflodacin represents a promising new oral therapy for drug-resistant infections caused by N. gonorrheae.<\/jats:p>","DOI":"10.1021\/acsinfecdis.0c00021","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T16:05:06Z","timestamp":1587744306000},"page":"1332-1345","source":"Crossref","is-referenced-by-count":160,"title":["Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic\nfor the Treatment of\n                    <i>Neisseria gonorrheae<\/i>\n                    , Including\nMulti-Drug-Resistant Isolates"],"prefix":"10.1021","volume":"6","author":[{"given":"Patricia A.","family":"Bradford","sequence":"first","affiliation":[{"name":"Antimicrobial Development Specialists, LLC , , ,","place":["Nyack, New York, United States, 10960"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7110-0493","authenticated-orcid":true,"given":"Alita A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-8738","authenticated-orcid":true,"given":"John","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-4015","authenticated-orcid":true,"given":"John P.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Entasis Therapeutics , , ,","place":["Waltham, Massachusetts, United States, 02451"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"9","key":"2026090108011696800_cit1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.15698\/mic2016.09.524","article-title":"Gonorrhea\n- an evolving disease of\nthe new millennium","volume":"3","author":"Hill","year":"2016","journal-title":"Microb Cell."},{"key":"2026090108011696800_cit2","volume-title":"Sexually Transmitted Disease Surveillance\n2018","author":"CDC.","year":"2019"},{"issue":"12","key":"2026090108011696800_cit3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143304","article-title":"Global Estimates\nof the Prevalence\nand Incidence of Four Curable Sexually Transmitted Infections in 2012\nBased on Systematic Review and Global Reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2026090108011696800_cit4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology\nof gonorrhoea:\na global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sexual Health."},{"key":"2026090108011696800_cit5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fmicb.2011.00102","article-title":"The Pathobiology\nof Neisseria gonorrhoeae Lower Female Genital Tract\nInfection","volume":"2","author":"Edwards","year":"2011","journal-title":"Front.\nMicrobiol."},{"issue":"2","key":"2026090108011696800_cit6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1651-2227.1987.tb10451.x","article-title":"Etiology and\ndiagnosis of neonatal conjunctivitis","volume":"76","author":"Sandstrom","year":"1987","journal-title":"Acta Paediatr."},{"issue":"3","key":"2026090108011696800_cit7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0049-0172(81)80002-9","article-title":"Disseminated gonococcal infection (DGI) and gonococcal\narthritis (GCA): II. Clinical manifestations, diagnosis, complications,\ntreatment, and prevention","volume":"10","author":"Masi","year":"1981","journal-title":"Semin. Arthritis\nRheum."},{"issue":"1","key":"2026090108011696800_cit8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/sti.75.1.3","article-title":"From epidemiological synergy to public\nhealth policy\nand practice: the contribution of other sexually transmitted diseases\nto sexual transmission of HIV infection","volume":"75","author":"Fleming","year":"1999","journal-title":"Sexually\nTransmitted Infections."},{"issue":"3","key":"2026090108011696800_cit9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance\nin Neisseria gonorrhoeae in the 21st century: past,\nevolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"issue":"12","key":"2026090108011696800_cit10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2217\/fmb.12.117","article-title":"Emergence of multidrug-resistant, extensively drug-resistant\nand untreatable gonorrhea","volume":"7","author":"Unemo","year":"2012","journal-title":"Future Microbiol."},{"issue":"3","key":"2026090108011696800_cit11","first-page":"1","article-title":"Sexually Transmitted Diseases Treatment Guidelines,\n2015","volume":"64","author":"CDC","year":"2015","journal-title":"Morbid Mortal Week Rep."},{"issue":"7","key":"2026090108011696800_cit12","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable\ngonorrhea?: detailed characterization of the first strain with high-level\nresistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob. Agents\nChemother."},{"issue":"3","key":"2026090108011696800_cit13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","article-title":"High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele\nin a successful international clone causes treatment failure","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"2026090108011696800_cit14","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/jac\/dks162","article-title":"Molecular\ncharacterization of two\nhigh-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain","volume":"67","author":"Camara","year":"2012","journal-title":"J.\nAntimicrob. Chemother."},{"issue":"27","key":"2026090108011696800_cit15","doi-asserted-by":"publisher","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea\ntreatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level\nazithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Eurosurveillance."},{"issue":"7","key":"2026090108011696800_cit16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1473-3099(18)30340-2","article-title":"Genetic characterisation\nof Neisseria gonorrhoeae resistant to both ceftriaxone\nand azithromycin","volume":"18","author":"Whiley","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"2026090108011696800_cit17","volume-title":"Global Priority List of Antibiotic-Resistant Bacteria to\nGuide Research, Discovery, and Development of New Antibiotics","author":"WHO.","year":"2017"},{"issue":"1","key":"2026090108011696800_cit18","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1038\/srep11827","article-title":"Responding\nto the challenge of untreatable gonorrhea: ETX0914, a first-in-class\nagent with a distinct mechanism-of-action against bacterial Type II\ntopoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"2026090108011696800_cit19","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1128\/AAC.00247-08","article-title":"Discovery\nand Characterization of QPT-1, the Progenitor of a New Class of Bacterial\nTopoisomerase Inhibitors","volume":"52","author":"Miller","year":"2008","journal-title":"Antimicrob. Agents\nChemother."},{"issue":"24","key":"2026090108011696800_cit20","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.1021\/ol503256h","article-title":"Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione\nDNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution\nat all Five Carbon Atoms of Pyridine","volume":"16","author":"Basarab","year":"2014","journal-title":"Org. Lett."},{"issue":"15","key":"2026090108011696800_cit21","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1021\/acs.jmedchem.5b00863","article-title":"Discovery\nof Novel DNA Gyrase Inhibiting\nSpiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone\nSubstituents Leading to a Clinical Candidate (ETX0914)","volume":"58","author":"Basarab","year":"2015","journal-title":"J. Med. Chem."},{"issue":"21","key":"2026090108011696800_cit22","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1021\/jm501174m","article-title":"Novel DNA\ngyrase inhibiting spiropyrimidinetriones\nwith a benzisoxazole scaffold: SAR and in vivo characterization","volume":"57","author":"Basarab","year":"2014","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026090108011696800_cit23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1517\/14740338.3.5.405","article-title":"The safety\nand efficacy of linezolid in orthopaedic\npractice for the treatment of infection due to antibiotic-resistant\norganisms","volume":"3","author":"Harwood","year":"2004","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"2026090108011696800_cit24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1039\/c3tx50028d","article-title":"Bone marrow\nmicronucleus frequencies in the rat after oral administration of cyclophosphamide,\nhexamethylphosphoramide or gemifloxacin for 2 and 28 days","volume":"2","author":"Doherty","year":"2013","journal-title":"Toxicol. Res."},{"key":"2026090108011696800_cit25","doi-asserted-by":"publisher","DOI":"10.1128\/ecosalplus.ESP-0010-2014","article-title":"DNA Topoisomerases","author":"Bush","year":"2015","journal-title":"EcoSal Plus"},{"issue":"Suppl 1","key":"2026090108011696800_cit26","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1086\/514923","article-title":"Bacterial\ntopoisomerases, anti-topoisomerases, and anti-topoisomerase resistance","volume":"27","author":"Hooper","year":"1998","journal-title":"Clin. Infect. Dis."},{"issue":"52","key":"2026090108011696800_cit27","doi-asserted-by":"publisher","first-page":"22363","DOI":"10.1073\/pnas.1016041108","article-title":"Evolutionary\ntwist on topoisomerases: Conversion of gyrase to topoisomerase IV","volume":"107","author":"Neuman","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"2026090108011696800_cit28","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1021\/bi00441a014","article-title":"Double-stranded DNA\ncleavage\/religation reaction of\neukaryotic topoisomerase II: evidence for a nicked DNA intermediate","volume":"28","author":"Zechiedrich","year":"1989","journal-title":"Biochemistry"},{"issue":"3","key":"2026090108011696800_cit29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase\nIV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol. Biol.\nRev."},{"issue":"34","key":"2026090108011696800_cit30","doi-asserted-by":"publisher","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","article-title":"Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914","volume":"290","author":"Kern","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"3","key":"2026090108011696800_cit31","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the Novel DNA\nGyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance\nin Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"1","key":"2026090108011696800_cit32","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/ncomms10048","article-title":"Structural basis of DNA gyrase inhibition\nby antibacterial QPT-1, anticancer drug etoposide and moxifloxacin","volume":"6","author":"Chan","year":"2015","journal-title":"Nat. Commun."},{"key":"2026090108011696800_cit33","unstructured":"Alm, R. A., Kutschke, A., Otterson, L., Lahiri, S., McLaughlin, R. E., Lewis, L. A., Su, X., Huband, M. D., Mueller, J. P., and Gardner, H., Eds.; Novel DNA gyrase inhibitor\nAZD0914: Low resistance potential and lack of cross-rsistance in Neisseria gonorrhoeae and Staphylococcus aureus. Poster F-1225c.  53rd Interscience Conference\non Antimicrobial Agents and Chemotherapy; Sept 10\u201313, 2013; Denver, CO."},{"key":"2026090108011696800_cit34","unstructured":"Kutschke, A., Basarab, G. S., Doig, P., Gowravaram, M., Kern, G., Mueller, J. P., and Stone, G., Eds.; Novel Mechanims\nof resistance\nagainst key Gram-positive pathgogens with benzisoxazoles: DNA gyrase\/topoisomerase\ninhibitors. Poster C1\u20131582.  53rd Interscience\nConference on Antimicrobial Agents and Chemotherapy; Sept\n10\u201313, 2013; Denver, CO."},{"issue":"12","key":"2026090108011696800_cit35","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/jac\/dkz376","article-title":"In vitro antimicrobial\ncombination\ntesting of and evolution of resistance to the first-in-class spiropyrimidinetrione\nzoliflodacin combined with six therapeutically relevant antimicrobials\nfor Neisseria gonorrhoeae","volume":"74","author":"Foerster","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"2026090108011696800_cit36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.04124-14","article-title":"In Vitro Antibacterial\nActivity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase\/Topoisomerase\nInhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative,\nand Atypical Bacteria","volume":"59","author":"Huband","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"2026090108011696800_cit37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.05.018","article-title":"In vitro\ngrowth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione","volume":"48","author":"Papp","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"2026090108011696800_cit38","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/AAC.00786-15","article-title":"High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914\n(AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014","volume":"59","author":"Unemo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026090108011696800_cit39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1128\/AAC.01211-15","article-title":"Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are\nSensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)","volume":"60","author":"Su","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"2026090108011696800_cit40","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1128\/AAC.03090-14","article-title":"High In Vitro Activity\nof the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase\nInhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea","volume":"58","author":"Jacobsson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090108011696800_cit41","unstructured":"Huband, M. D., Flamm, R. K., Rhomberg, P. R., Mueller, J. P., and Jones, R. N., Eds.; In vitro\nactivity of AZD0914: a new benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae.  53rd Interscience\nConference on Antimicrobial Agents and Chemotherapy; Sept\n10\u201313, 2013; Denver, CO."},{"issue":"12","key":"2026090108011696800_cit42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01479-19","article-title":"High In Vitro Susceptibility\nto the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive\nClinical Neisseria gonorrhoeae Isolates from Thailand\nand South Africa","volume":"63","author":"Jacobsson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl\n2","key":"2026090108011696800_cit43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/00003495-199958002-00003","article-title":"Mechanisms\nof fluoroquinolone resistance: an update 1994\u20131998","volume":"58","author":"Piddock","year":"1999","journal-title":"Drugs"},{"key":"2026090108011696800_cit44","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01377","article-title":"Genetic\nResistance\nDeterminants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic\nFunctions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914)\nin Neisseria gonorrhoeae","volume":"6","author":"Foerster","year":"2015","journal-title":"Front. Microbiol."},{"issue":"10","key":"2026090108011696800_cit45","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1128\/AAC.01016-15","article-title":"In Vitro Activity\nof AZD0914, a Novel Bacterial DNA\nGyrase\/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive\nand Fastidious Gram-Negative Pathogens","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"6","key":"2026090108011696800_cit46","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1128\/AAC.04945-14","article-title":"In Vitro Antibacterial\nActivity of AZD0914 against Human Mycoplasmas and Ureaplasmas","volume":"59","author":"Waites","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"2026090108011696800_cit47","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/jac\/dky022","article-title":"In vitro activity\nof zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant\nand antimicrobial-susceptible Mycoplasma genitalium strains","volume":"73","author":"Damia\u0303o Gouveia","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"2026090108011696800_cit48","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1128\/AAC.03920-14","article-title":"In Vitro Activity of AZD0914, a Novel\nDNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae","volume":"58","author":"Kohlhoff","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090108011696800_cit49","unstructured":"Huband, M. D., Giacobbe, R. A., Lane, D. J., Minyard, M., Panchal, R. G., Mueller, J. P., and Bradford, P. A., Eds.; In Vitro\nAntibacterial Activity of AZD0914: A New Spiropyrimidinetrione Bacterial\nDNA Gyrase Inhibitor against Potential Agents of Bioterrorism. Poster\nF-462.  54th Interscience Conference on Antimicrobial\nAgents and Chemotherapy; September 5\u20139, 2014; Washington, DC."},{"key":"2026090108011696800_cit50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12866-016-0838-9","article-title":"Time-kill\ncurve analysis and pharmacodynamic modelling for in vitro evaluation\nof antimicrobials against Neisseria gonorrhoeae","volume":"16","author":"Foerster","year":"2016","journal-title":"BMC Microbiol."},{"issue":"6","key":"2026090108011696800_cit51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156690","article-title":"Comparative Activity\nof Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella\npneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia\nAssessed by Minimum Inhibitory Concentrations and Time-Kill Studies","volume":"11","author":"Grillon","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"2026090108011696800_cit52","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02047-16","article-title":"In Vitro Activity of Gepotidacin\n(GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"1","key":"2026090108011696800_cit53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1128\/AAC.44.1.186-189.2000","article-title":"Postantibiotic\nEffects of Grepafloxacin Compared to Those of Five Other Agents against\n12 Gram-Positive and -Negative Bacteria","volume":"44","author":"Spangler","year":"2000","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"9","key":"2026090108011696800_cit54","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/AAC.49.9.3963-3965.2005","article-title":"Postantibiotic Effect of DX-619 against\n16 Gram-Positive\nOrganisms","volume":"49","author":"Pankuch","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026090108011696800_cit55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy,\nantagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"2026090108011696800_cit56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.diagmicrobio.2016.03.007","article-title":"Effect of Susceptibility\nTesting Conditions on the In Vitro Antibacterial Activity of ETX0914","volume":"87","author":"Giacobbe","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"4","key":"2026090108011696800_cit57","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1128\/AAC.24.4.568","article-title":"In vitro\nactivity of ciprofloxacin (Bay o 9867)","volume":"24","author":"Fass","year":"1983","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"5","key":"2026090108011696800_cit58","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/jac\/dkh180","article-title":"Comparative study of the in vitro activity of a new fluoroquinolone,\nABT-492","volume":"53","author":"Harnett","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090108011696800_cit59","volume-title":"M07-A11 Methods for Dilution Antimicrobial\nSusceptibility\nTests for Bacteria That Grow Aerobically","author":"CLSI.","year":"2018","edition":"10"},{"issue":"9","key":"2026090108011696800_cit60","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00567-19","article-title":"Determination\nof MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin","volume":"57","author":"Miller","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"2026090108011696800_cit61","volume-title":"M100-S30 Performance Standards for Antimicrobial\nSusceptibility\nTesting","author":"CLSI.","year":"2020"},{"key":"2026090108011696800_cit62","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00107","article-title":"Estradiol-Treated Female Mice as Surrogate\nHosts for Neisseria gonorrhoeae Genital Tract Infections","volume":"2","author":"Jerse","year":"2011","journal-title":"Front. Microbiol."},{"key":"2026090108011696800_cit63","unstructured":"VanScoy, B. D., Fikes, S., Bhavnani, S. M., Conde, H., Scangarella-Oman, N. E., and Ambrose, P. G., Eds. A Hollow-Fiber\nInfection Model to Evaluate the Prevention of On-Therapy Resistance\nof Neisseria gonorrhoeae to Gepotidacin.  STD Prevention Conference; Aug 27\u201330, 2018; Washington, DC."},{"issue":"5","key":"2026090108011696800_cit64","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin\nin seriously\nill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090108011696800_cit65","unstructured":"Newman, J. V., Luo, W., Farrington, K., Schuck, V. J. A., Tanudra, M. A., Beaudoin, M. E., Singh, R., and Mueller, J. P., Eds. Pharmacodynamics\nof AZD0914 against Staphylococcus aureus. Poster F-1225a.  53rd Interscience\nConference on Antimicrobial Agents and Chemotherapy; Sept\n10\u201313, 2013; Denver, CO."},{"key":"2026090108011696800_cit66","unstructured":"Aksenov, S., Schuck, V., Vishwanathan, K., Newman, J., Huband, M., Gardner, H., and Mueller, J.,\neditors. Dose\nSelection for a Phase II Study of AZD0914: A Novel Agent against Neisseria gonorrhoeae. Poster A-1183.  54th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 5\u20139, 2014; Washington,\nDC."},{"key":"2026090108011696800_cit67","unstructured":"Schuck, V. J. A., Vishwanathan, K., Newman, J. V., Huband, M. D., Kern, G., Basarab, G., and Mueller, J. P., Eds. Use of Surrogate Pathogen Approach to Predict AZD0914 Efficacious\nDose Against Neisseria gonorrhoeae. Poster F-1225d.  53rd Interscience Conference on Antimicrobial Agents and\nChemotherapy; Sept 10\u201313, 2013; Denver, CO."},{"issue":"19","key":"2026090108011696800_cit68","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-Dose Zoliflodacin (ETX0914)\nfor Treatment of Urogenital Gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N. Engl.\nJ. Med."},{"issue":"3","key":"2026090108011696800_cit69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01644-18","article-title":"Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model","volume":"63","author":"Connolly","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"2026090108011696800_cit70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1574886308666140106154754","article-title":"Third and fourth generation\nfluoroquinolone antibacterials: a systematic review of safety and\ntoxicity profiles","volume":"9","author":"Sousa","year":"2014","journal-title":"Curr. Drug Saf."},{"issue":"1","key":"2026090108011696800_cit71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/00498254.2016.1156186","article-title":"Absorption,\ndistribution, metabolism and elimination\nof 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases\nin rodents","volume":"47","author":"Guo","year":"2017","journal-title":"Xenobiotica"},{"issue":"1","key":"2026090108011696800_cit72","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01808-18","article-title":"Single-Dose Pharmacokinetics, Excretion,\nand Metabolism\nof Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy\nVolunteers","volume":"63","author":"O\u2019Donnell","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026090108011696800_cit73","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/cid\/cix485","article-title":"Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone\nSusceptibility, Hawaii, 2016","volume":"65","author":"Katz","year":"2017","journal-title":"Clin. Infect.\nDis."},{"issue":"5","key":"2026090108011696800_cit74","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3201\/eid2305.170088","article-title":"Azithromycin\nResistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA","volume":"23","author":"Papp","year":"2017","journal-title":"Emerging\nInfect. Dis."},{"issue":"2","key":"2026090108011696800_cit75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002499","article-title":"Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: A retrospective study\nof national surveillance data from 2013 to 2016","volume":"15","author":"Yin","year":"2018","journal-title":"PLoS Med."},{"issue":"1","key":"2026090108011696800_cit76","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1080\/22221751.2019.1681242","article-title":"Identification of multidrug-resistant Neisseria gonorrhoeae isolates with combined resistance\nto both ceftriaxone and azithromycin, China, 2017\u20132018","volume":"8","author":"Yuan","year":"2019","journal-title":"Emerging Microbes Infect."},{"issue":"3","key":"2026090108011696800_cit77","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000929","article-title":"Antimicrobial Resistance\nin Neisseria gonorrhoeae: Proceedings of the STAR\nSexually Transmitted Infection-Clinical Trial Group Programmatic Meeting","volume":"46","author":"Cristillo","year":"2019","journal-title":"Sex. Transm. Dis."},{"issue":"7","key":"2026090108011696800_cit78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant\ngonorrhea: A research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med."},{"issue":"2","key":"2026090108011696800_cit79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1586\/14787210.2016.1134315","article-title":"New treatment options for infections\ncaused by increasingly\nantimicrobial-resistant Neisseria gonorrhoeae","volume":"14","author":"Lee","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.0c00021","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1332\/67429299\/acsinfecdis.0c00021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/6\/1332\/67429299\/acsinfecdis.0c00021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:01:25Z","timestamp":1788264085000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/6\/6\/1332\/607858\/Zoliflodacin-An-Oral-Spiropyrimidinetrione"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,24]]},"published-print":{"date-parts":[[2020,6,12]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.0c00021","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}